{"slug":"frontier","tag":"frontier","variants":["frontier"],"description":"Technologies at the edge of what is possible: early clinical or preclinical, not yet routine.","count":72,"kinds":{"technology":64,"company":8},"related":[{"slug":"promising","tag":"promising","shared":19},{"slug":"radical","tag":"radical","shared":14},{"slug":"concept","tag":"concept","shared":1},{"slug":"early-stage","tag":"early-stage","shared":1},{"slug":"yc","tag":"yc","shared":1}],"records":[{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/","status":"phase-1","tldr":"An experimental PET scan that shows whether a tumour carries the TROP2 protein, so doctors could pick the right ADC before giving it."},{"id":"flash-rt","kind":"technology","name":"FLASH radiotherapy","route":"/technologies/flash-rt/","status":"phase-1","tldr":"Delivering an entire dose in under a second, which in animals spares healthy tissue while still killing the tumour."},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","status":"phase-3","tldr":"Like radioligand therapy but with alpha particles: far more destructive over a much shorter range, so single cells can be killed with less collateral damage."},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","status":"phase-2","tldr":"Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy."},{"id":"antisense-sirna","kind":"technology","name":"Oligonucleotide therapeutics","route":"/technologies/antisense-sirna/","status":"phase-2","tldr":"Oligonucleotide therapeutics are short synthetic strands of genetic code that silence a specific cancer gene."},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/","status":"phase-3","tldr":"A bispecific ADC is an ADC whose antibody grabs two different proteins on the cancer cell, so it sticks better to tumour and less to healthy tissue."},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/","status":"phase-1","tldr":"A dual-payload ADC is an ADC carrying two different poisons at once, so the tumour cannot escape by becoming resistant to one."},{"id":"degrader-antibody-conjugate","kind":"technology","name":"Degrader-antibody conjugate (DAC)","route":"/technologies/degrader-antibody-conjugate/","status":"phase-1","tldr":"An ADC that delivers a protein-destroying molecule instead of chemotherapy, hitting targets inside the cell that were previously unreachable."},{"id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/","status":"phase-1","tldr":"An immune-stimulating antibody conjugate (ISAC) is an ADC whose payload wakes up the immune system inside the tumour rather than poisoning the cell."},{"id":"masked-adc","kind":"technology","name":"Masked / conditionally active ADC","route":"/technologies/masked-adc/","status":"phase-2","tldr":"An ADC wearing a mask that only comes off inside the tumour, so it ignores the same protein on healthy tissue."},{"id":"sting-agonist","kind":"technology","name":"STING & innate immune agonists","route":"/technologies/sting-agonist/","status":"phase-2","tldr":"Drugs that trigger the cell's built-in 'virus alarm' inside tumours to summon immune cells."},{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/","status":"phase-1","tldr":"Instead of engineering T cells in a factory, an injection reprograms them inside the patient's body."},{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/","status":"phase-1","tldr":"Putting the cancer-seeking receptor on natural killer cells or macrophages instead of T cells, which could be safer and off-the-shelf."},{"id":"armored-car","kind":"technology","name":"Armoured, logic-gated & next-gen CARs","route":"/technologies/armored-car/","status":"phase-1","tldr":"Upgraded CAR-T cells that also secrete immune boosters, resist exhaustion, or only fire when two signals are present."},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/","status":"emerging","tldr":"Pathology and radiology foundation models are AI networks pretrained without labels on over a million slides or scans (Virchow used 1.5 million), then adapted with small task heads to predict mutations, prognosis or treatment response from routine images. They power the FDA-cleared ArteraAI tools, but validation across hospitals and how regulators treat general-purpose models remain unsettled."},{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/","status":"phase-2","tldr":"Using machine learning to pick targets, design molecules and antibodies, and predict which ADC will work."},{"id":"finaldose","kind":"company","name":"FinalDose","route":"/companies/finaldose/","tldr":"Y Combinator Spring 2026 start-up building a programmable DNA-targeting drug: a molecule that recognises a cancer-specific DNA sequence inside a cell and triggers a kill switch only there."},{"id":"orna-therapeutics","kind":"company","name":"Orna Therapeutics (Eli Lilly)","route":"/companies/orna-therapeutics/","tldr":"Circular-RNA in vivo CAR company bought by Eli Lilly for about $2.4B in February 2026."},{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","route":"/companies/umoja-biopharma/","tldr":"In vivo CAR-T company using lentiviral vectors (VivoVec); first CD22-directed in vivo CAR-T cleared for US trials in 2026."},{"id":"interius","kind":"company","name":"Interius BioTherapeutics","route":"/companies/interius/","tldr":"Penn spin-out that dosed the first patient ever with a durable in vivo CAR gene therapy (INT2104, CD20) in the INVISE trial."},{"id":"isomorphic-labs","kind":"company","name":"Isomorphic Labs","route":"/companies/isomorphic-labs/","tldr":"Alphabet's AlphaFold-derived drug design company; its first AI-designed oncology candidate was cleared for human trials in January 2026 after a $2.1B raise."},{"id":"generate-biomedicines","kind":"company","name":"Generate:Biomedicines","route":"/companies/generate-biomedicines/","tldr":"Generative-AI protein design company (Flagship) that went public in 2026 and is testing an antibody that neutralises leaked ADC payload to reduce side effects."},{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","tldr":"Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3."},{"id":"arsenal-bio","kind":"company","name":"Arsenal Biosciences","route":"/companies/arsenal-bio/","tldr":"Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer."},{"id":"programmable-dna-targeting-therapeutics","kind":"technology","name":"Programmable DNA-targeting therapeutics","route":"/technologies/programmable-dna-targeting-therapeutics/","status":"preclinical","tldr":"Programmable DNA-targeting therapeutics are an experimental idea: a drug that reads a cell's DNA, recognises a cancer-specific sequence, and kills only cells that carry it. Change the guide, and the same drug becomes a new drug."},{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/","status":"established","tldr":"Fragmentomics reads the sizes and positions of DNA fragments in blood, not the mutations. Cancer cells die messily and leave a recognisable fragmentation pattern."},{"id":"adc-payload-neutralizer","kind":"technology","name":"ADC payload neutralisers","route":"/technologies/adc-payload-neutralizer/","status":"phase-1","tldr":"An ADC payload neutraliser is an antibody given alongside an ADC that mops up the poison once it leaks into the bloodstream, so the ADC can hit the tumour with fewer side effects."},{"id":"in-vivo-gene-editing-cancer","kind":"technology","name":"In vivo base and prime editing for cancer","route":"/technologies/in-vivo-gene-editing-cancer/","status":"concept","tldr":"In vivo base and prime editing would rewrite a cancer's DNA letter by letter inside the body. It works in the liver for inherited disease; nobody has yet corrected a cancer this way in a person."},{"id":"epigenetic-editing","kind":"technology","name":"Epigenetic editing (durable gene silencing)","route":"/technologies/epigenetic-editing/","status":"concept","tldr":"Switching a gene off for good without changing the DNA sequence, by writing chemical marks onto it."},{"id":"self-amplifying-rna","kind":"technology","name":"Self-amplifying and circular RNA therapeutics","route":"/technologies/self-amplifying-rna/","status":"phase-1","tldr":"RNA drugs that copy themselves inside the cell, or are made as a loop so they last longer. Both aim to get more protein from a smaller dose."},{"id":"stroma-directed-car","kind":"technology","name":"CAR-T against stroma: fibroblasts and myeloid cells","route":"/technologies/stroma-directed-car/","status":"preclinical","tldr":"Instead of attacking the cancer cell, engineering T cells to strip away the scaffolding and the suppressive immune cells that protect it."},{"id":"engineered-bacteria-therapy","kind":"technology","name":"Engineered bacteria as living cancer drugs","route":"/technologies/engineered-bacteria-therapy/","status":"phase-2","tldr":"Bacteria that seek out the low-oxygen core of tumours, then manufacture a drug on the spot."},{"id":"phage-delivery","kind":"technology","name":"Bacteriophage-based tumour delivery","route":"/technologies/phage-delivery/","status":"preclinical","tldr":"Bacteriophage delivery uses viruses that infect bacteria, not human cells, as engineered shells whose coat proteins display tumour-homing peptides or antigens and carry drugs or vaccines. They are cheap and cannot replicate in people, but the work is preclinical: no oncology phage trial had reported efficacy by 2026, and the body clears them quickly."},{"id":"microbiome-modulation-io","kind":"technology","name":"Microbiome modulation to unlock immunotherapy","route":"/technologies/microbiome-modulation-io/","status":"phase-2","tldr":"Changing the gut bacteria of a patient whose immunotherapy stopped working, in the hope of restarting the response."},{"id":"tumour-microbiome-targeting","kind":"technology","name":"Targeting the tumour's own microbes","route":"/technologies/tumour-microbiome-targeting/","status":"preclinical","tldr":"Some tumours contain bacteria and fungi that shelter cancer cells and break down chemotherapy. Killing them may make treatment work."},{"id":"dna-origami-nanorobots","kind":"technology","name":"DNA origami nanorobots","route":"/technologies/dna-origami-nanorobots/","status":"preclinical","tldr":"Folded DNA machines that open only when they touch a tumour, releasing a payload or clotting the tumour's blood supply."},{"id":"magnetic-nanoparticle-hyperthermia","kind":"technology","name":"Magnetic nanoparticle hyperthermia","route":"/technologies/magnetic-nanoparticle-hyperthermia/","status":"phase-2","tldr":"Magnetic nanoparticle hyperthermia injects iron-oxide nanoparticles into a tumour and heats them from outside with an alternating magnetic field."},{"id":"photothermal-nanoparticles","kind":"technology","name":"Photothermal (plasmonic) nanoparticle ablation","route":"/technologies/photothermal-nanoparticles/","status":"phase-2","tldr":"Gold nanoshells that accumulate in a tumour and cook it when a near-infrared laser is shone on them."},{"id":"sonodynamic-therapy","kind":"technology","name":"Sonodynamic therapy","route":"/technologies/sonodynamic-therapy/","status":"phase-2","tldr":"A drug that does nothing until ultrasound hits it, then kills the cells that took it up. Being tested in brain tumours because sound reaches where light cannot."},{"id":"radiodynamic-therapy","kind":"technology","name":"Radiodynamic therapy and radiosensitising nanoparticles","route":"/technologies/radiodynamic-therapy/","status":"phase-2","tldr":"Nanoparticles that turn ordinary radiotherapy X-rays into a much bigger dose exactly where they sit."},{"id":"vhee-radiotherapy","kind":"technology","name":"Very-high-energy electron therapy","route":"/technologies/vhee-radiotherapy/","status":"preclinical","tldr":"VHEE radiotherapy fires electrons at 100 to 250 MeV, energies that reach deep tumours and can be steered by magnets, aiming to deliver FLASH-speed radiation from a machine smaller and cheaper than a proton facility. It is still at the accelerator-development and preclinical stage: no patient had been treated by September 2026."},{"id":"proton-arc-therapy","kind":"technology","name":"Proton arc therapy","route":"/technologies/proton-arc-therapy/","status":"phase-1","tldr":"Rotating the proton beam continuously around the patient instead of firing from a few fixed angles, to spread the entrance dose and sharpen the target dose."},{"id":"lattice-radiotherapy","kind":"technology","name":"Lattice and GRID radiotherapy","route":"/technologies/lattice-radiotherapy/","status":"phase-2","tldr":"Lattice radiotherapy deliberately treats a bulky tumour unevenly, placing peaks of tumour-destroying dose at spaced points inside it while the tissue between receives far less, relying on bystander and immune effects to extend the kill. It runs on standard linear accelerators, but evidence is mostly palliative and single-arm, and the mechanism is unsettled."},{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","status":"preclinical","tldr":"Auger-electron therapy uses radioactive atoms such as iodine-125 or terbium-161 that release cascades of low-energy electrons travelling only nanometres to micrometres, so they kill a cell only if the atom sits on or inside its DNA and spare the neighbours. Terbium-161 can replace lutetium-177 in existing PSMA ligands; true nuclear delivery remains preclinical."},{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","status":"preclinical","tldr":"Actinium-225 releases four alpha particles as it decays, but the daughters escape and irradiate the kidneys and salivary glands. Nanocarriers try to hold them in place."},{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","status":"phase-1","tldr":"Adding a PARP or ATR inhibitor to a radioactive drug so the tumour cannot repair the damage the radiation causes."},{"id":"nerve-tumour-denervation","kind":"technology","name":"Cancer neuroscience: cutting the nerve supply","route":"/technologies/nerve-tumour-denervation/","status":"phase-2","tldr":"Tumours recruit nerves and use nerve signals to grow. Blocking that traffic, with beta-blockers or botulinum toxin, is being tested."},{"id":"cachexia-therapy","kind":"technology","name":"Cachexia-directed therapy (GDF-15 blockade)","route":"/technologies/cachexia-therapy/","status":"phase-3","tldr":"Cachexia-directed therapy treats cancer wasting by blocking GDF-15, a hormone that rises in advanced cancer and acts on the brainstem to suppress appetite. Pfizer's antibody ponsegromab improved weight in a phase 2 trial and is in phase 2/3 in pancreatic cancer cachexia; whether weight gain translates into function is the open question."},{"id":"chronotherapy","kind":"technology","name":"Chronotherapy: timing treatment to the body clock","route":"/technologies/chronotherapy/","status":"phase-2","tldr":"Giving the same drug at a different time of day, because the body clock changes how much damage it does and how well the immune system responds."},{"id":"metabolic-therapy","kind":"technology","name":"Metabolic therapy: starving the tumour of a nutrient","route":"/technologies/metabolic-therapy/","status":"phase-2","tldr":"Removing an amino acid or nutrient that certain tumours cannot make for themselves, while normal cells can."},{"id":"senescence-targeting","kind":"technology","name":"Senolytics and senescence-directed therapy","route":"/technologies/senescence-targeting/","status":"preclinical","tldr":"Chemotherapy leaves behind zombie cells that will not divide but poison their neighbours. Senolytics aim to clear them."},{"id":"il12-electroporation","kind":"technology","name":"Intratumoural gene electrotransfer (IL-12 plasmid)","route":"/technologies/il12-electroporation/","status":"phase-2","tldr":"Intratumoural gene electrotransfer injects a plasmid carrying the interleukin-12 gene into a tumour and pushes it into cells with electric pulses, so this T-cell-activating cytokine is made locally instead of at the toxic doses intravenous IL-12 needed. It produced responses with pembrolizumab in anti-PD-1-resistant melanoma, but the sponsor's programmes have stalled."},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/","status":"phase-1","tldr":"Designing a protein from scratch on a computer to grip a chosen target, instead of finding one in an animal or a library."},{"id":"molecular-glue-platforms","kind":"technology","name":"Molecular glue discovery platforms","route":"/technologies/molecular-glue-platforms/","status":"phase-1","tldr":"Molecular glues are small molecules that stick two proteins together so the cell destroys one of them. They are smaller and more drug-like than bifunctional degraders."},{"id":"antibody-oligonucleotide-conjugates","kind":"technology","name":"Antibody-oligonucleotide conjugates","route":"/technologies/antibody-oligonucleotide-conjugates/","status":"preclinical","tldr":"An ADC that carries a gene-silencing strand instead of a chemotherapy, so it can switch a protein off rather than poison the cell."},{"id":"logic-gated-therapeutics","kind":"technology","name":"Logic-gated therapeutics (AND, NOT gates)","route":"/technologies/logic-gated-therapeutics/","status":"phase-1","tldr":"Cells or drugs that fire only when two conditions are true at once, so healthy tissue expressing just one of them is spared."},{"id":"in-situ-vaccination","kind":"technology","name":"In situ vaccination","route":"/technologies/in-situ-vaccination/","status":"phase-2","tldr":"Treating one tumour so aggressively that the immune system learns to attack every other one, using the tumour itself as the vaccine."},{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/","status":"phase-2","tldr":"Cancer interception vaccines immunise people who do not yet have cancer but carry a high inherited risk, such as Lynch syndrome carriers, against the antigens their future tumour is predicted to express, so memory T cells remove transformed cells early. Because healthy people accept risk for a probabilistic benefit, the safety bar is far higher and trials take years."},{"id":"trained-innate-immunity","kind":"technology","name":"Trained innate immunity","route":"/technologies/trained-innate-immunity/","status":"phase-2","tldr":"Giving the innate immune system a memory, so monocytes and NK cells respond harder the next time they meet a tumour."},{"id":"histotripsy-immune-priming","kind":"technology","name":"Histotripsy as an immune primer","route":"/technologies/histotripsy-immune-priming/","status":"phase-1","tldr":"Destroying a tumour mechanically with sound, rather than heat, leaves the debris intact enough for the immune system to learn from it."},{"id":"mechanobiology-therapy","kind":"technology","name":"Targeting tumour mechanics and pressure","route":"/technologies/mechanobiology-therapy/","status":"preclinical","tldr":"Stiff, high-pressure tumours squeeze their own blood vessels shut, keeping drugs out. Softening them is a way in."},{"id":"hypoxia-activated-therapy","kind":"technology","name":"Hypoxia-activated prodrugs","route":"/technologies/hypoxia-activated-therapy/","status":"phase-2","tldr":"A harmless molecule that turns into a poison only where there is no oxygen, which in the body means inside a tumour."},{"id":"digital-twins-trials","kind":"technology","name":"Digital twins and virtual control arms","route":"/technologies/digital-twins-trials/","status":"emerging","tldr":"Using a model of what would have happened to a patient on standard treatment, so fewer people have to be randomised to it."},{"id":"n-of-1-platforms","kind":"technology","name":"N-of-1 and rapid platform trials","route":"/technologies/n-of-1-platforms/","status":"emerging","tldr":"Building a trial around one patient, or letting one trial swap drugs in and out as evidence accumulates."},{"id":"continuous-ctdna-monitoring","kind":"technology","name":"Continuous and near-continuous ctDNA monitoring","route":"/technologies/continuous-ctdna-monitoring/","status":"concept","tldr":"Instead of testing blood every three months, sampling constantly, so a relapse is caught the week it starts."},{"id":"breath-vocs","kind":"technology","name":"Breath and volatile-organic-compound detection","route":"/technologies/breath-vocs/","status":"phase-2","tldr":"Smelling cancer: measuring the trace chemicals a tumour puts into exhaled breath."},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/","status":"phase-3","tldr":"Testing cheap old drugs, aspirin, metformin, statins, beta-blockers, as cancer treatments, because they are safe, available and sometimes work."},{"id":"total-body-pet-screening","kind":"technology","name":"Total-body PET for screening and ultra-low-dose imaging","route":"/technologies/total-body-pet-screening/","status":"concept","tldr":"Scanners sensitive enough to image the whole body in seconds at a fraction of the radiation dose, which raises the question of whether healthy people should be scanned at all."},{"id":"quantum-dot-imaging","kind":"technology","name":"Quantum-dot and molecular ultrasound imaging agents","route":"/technologies/quantum-dot-imaging/","status":"preclinical","tldr":"Brighter, longer-lasting fluorescent particles and targeted microbubbles that make tumours visible during surgery or on an ultrasound scan."},{"id":"organoid-guided-therapy-scale","kind":"technology","name":"Organoid-guided therapy at scale","route":"/technologies/organoid-guided-therapy-scale/","status":"phase-2","tldr":"Organoid-guided therapy means routinely growing a piece of each patient's tumour and testing drugs on it before choosing, rather than relying on genetics alone."},{"id":"spatial-omics-guided-therapy","kind":"technology","name":"Spatial-omics-guided treatment selection","route":"/technologies/spatial-omics-guided-therapy/","status":"emerging","tldr":"Choosing treatment from a map of where each cell type sits in the tumour, not just from a list of its mutations."},{"id":"exosome-therapeutics","kind":"technology","name":"Engineered exosomes as drug carriers","route":"/technologies/exosome-therapeutics/","status":"phase-1","tldr":"Loading the tiny vesicles cells naturally use to talk to each other with a cancer drug, so the body treats the carrier as its own."}]}